The FDA’s top vaccine official raised concerns that a sharply accelerated process to review and formally approve Pfizer’s Covid-19 vaccine would undermine public confidence in the shots, leading to a series of vigorous exchanges between her and the agency’s senior leaders.
Phil Krause
The emails, contained…
Be the first to comment